One Thing In Common
Mark Cuban campaigned for Kamala Harris. He raised money for her. He appeared alongside her at “Business Leaders for Harris” events and publicly endorsed her all the way through Election Day. On Monday, he stood in the White House with the man who beat her and announced one of the more genuinely bipartisan policy achievements of the current term.
“Republicans want cheaper drugs, independents want cheaper drugs, Democrats want cheaper drugs, and together I think we’re going to do something special,” Cuban said at the TrumpRx expansion event.
Trump, for his part, acknowledged the awkward history with characteristic good humor. He called Cuban’s Harris endorsement a “big mistake” and said he has “always respected” him — which, for Trump, is about as gracious as it gets. The president offered his own distillation of what the two men have in common: “We want to make people better and keep them wealthy.”
Whatever else one thinks about that formulation, it produced a concrete policy outcome Monday. The administration announced the addition of more than 600 generic medications to TrumpRx.gov, made possible by formal partnerships with Cuban’s Cost Plus Drug Company, Amazon Pharmacy, and GoodRx. The platform, originally launched in February to make Most Favored Nation drug prices available directly to consumers for name-brand medications, is now significantly broader in scope — creating, in Trump’s framing, “one source to ensure that they’re getting the lowest possible costs on their prescriptions.”
Why This Matters — And Why It’s Underreported
Prescription drug pricing in the United States is a genuine failure of market design — an area where ideological conservatives and progressives share a legitimate grievance, even if they propose different solutions. The existing pharmaceutical pricing ecosystem is riddled with middlemen: pharmacy benefit managers, insurers, and wholesale distributors whose primary function is extracting margin from transactions between drug manufacturers and patients. That system produces the absurdity of the same pill costing $200 in the U.S. and $20 in Canada, not because American patients are getting something better, but because the architecture of American drug distribution has been designed to extract maximum rent from a captive market.
Cuban recognized this years before Monday’s event. He built Cost Plus Drug Company in 2022 specifically to circumvent the middlemen — offering generic drugs with complete price transparency: manufacturer cost plus a flat 15% markup, plus a $5 pharmacy labor fee, plus $5.25 shipping. The model’s success validated the underlying diagnosis. And his willingness to partner with the Trump administration’s parallel effort — despite his political history — reflects a pragmatic judgment that outcomes matter more than branding.
HHS adviser Chris Klomp articulated the administration’s long-term ambition at the event. “This president has set us on a course to permanently benefit from lower drug prices as a country,” he said. “The foundation is built, the market is engaged, the future is affordable.” That framing goes beyond a single announcement. The administration has also negotiated separate deals with 17 major pharmaceutical manufacturers to offer medications at Most Favored Nation pricing levels — deals that remain under congressional scrutiny but represent a genuine attempt to reshape the underlying economics.
The Midterm Politics — And The Broader Picture
It would be naive to pretend there’s no political timing to the announcement. Drug costs are a leading voter concern heading into November, and the affordability narrative is the administration’s most important midterm message at a moment when Iran war costs and gas prices are creating economic headwinds. The Monday event was partly about policy and partly about reminding voters that the White House is fighting for their wallets at the pharmacy counter.
That said, the substance is real. TrumpRx’s expansion to generic medications is a meaningful broadening of access — generics account for roughly 90% of all prescriptions dispensed in the United States and represent the clearest opportunity for immediate cost savings for uninsured patients and those with high deductibles. Cuban noted before the event that the one thing he thought TrumpRx needed was exactly what it got on Monday: a robust generic drug catalog.
The fact that a man who endorsed Kamala Harris is standing at the White House saying “this is good policy” should carry some bipartisan weight with the Americans who are skeptical of anything that comes out of the Trump administration. Cuban has no incentive to be there unless he believes the program actually helps patients. He said as much when the administration’s early version launched: “Reality is, it’s saving patients money on IVF and a few other drugs. A lot of money. IMO, anything that saves patients money is a win.” On this, at least, Trump and Cuban have indeed found something in common.
